Thyroid autoimmunity and hypothyroidism during long-term treatment with recombinant interferon-alpha

Area of Science:

• Endocrinology
• Hematology
• Immunology

Background:

• Myeloproliferative and myelodysplastic syndromes are a group of blood cancers.
• Recombinant interferon-alpha (rIFN-alpha) is used in treating these conditions.
• The potential for autoimmune side effects with rIFN-alpha is a concern.

Purpose of the Study:

• To investigate the occurrence of thyroid autoimmunity in patients treated with rIFN-alpha.
• To determine if rIFN-alpha induces or exacerbates thyroid autoimmunity.
• To assess the reversibility and clinical implications of rIFN-alpha-associated thyroid autoimmunity.

Main Methods:

• A cohort of 45 patients with myeloproliferative or myelodysplastic syndromes treated with rIFN-alpha for 1-4 years was studied.
• Thyroid autoimmunity was monitored during rIFN-alpha treatment.
• Changes in thyroid autoimmunity and function were assessed after rIFN-alpha withdrawal.

Main Results:

• Thyroid autoimmunity increased to over 20% during rIFN-alpha treatment.
• Autoimmunity severity and frequency decreased after rIFN-alpha withdrawal, indicating reversibility.
• Patients with pre-existing thyroid antibodies were more prone to exacerbations.

Conclusions:

• Thyroid autoimmunity and hypothyroidism are potential side effects of long-term rIFN-alpha therapy.
• rIFN-alpha appears to enhance pre-existing thyroid autoimmunity rather than induce new autoimmunity.
• Monitoring for thyroid autoimmunity is recommended in patients receiving prolonged rIFN-alpha treatment.